{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:41Z","timestamp":1792677641378,"version":"4.5.0"},"reference-count":60,"publisher":"Radcliffe Medical Media Ltd","issue":"3","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.<\/jats:p>","DOI":"10.15420\/cfr.2019.11.2","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T08:15:26Z","timestamp":1573114526000},"page":"133-139","source":"Crossref","is-referenced-by-count":67,"title":["Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice"],"prefix":"10.15420","volume":"5","author":[{"given":"Vasiliki","family":"Bistola","sequence":"first","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Arfaras-Melainis","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftihia","family":"Polyzogopoulou","sequence":"additional","affiliation":[{"name":"Emergency Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parissis","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","DOI":"10.1002\/ejhf.592"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","DOI":"10.1093\/eurjhf\/hfq154"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","DOI":"10.1002\/ejhf.260"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Venkatason P, Zubairi YZ, Wan Ahmad WA, et al. In-hospital mortality of cardiogenic shock complicating ST-elevation myocardial infarction in Malaysia: a retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry. BMJ Open 2019;9:e025734.","DOI":"10.1136\/bmjopen-2018-025734"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Inotropes in acute heart failure","DOI":"10.1002\/cce2.59"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Cardiac inotropes: current agents and future directions","DOI":"10.1093\/eurheartj\/ehr026"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease","DOI":"10.1161\/CIRCULATIONAHA.107.728840"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-43.","DOI":"10.1016\/S0140-6736(00)03495-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial","DOI":"10.1016\/j.ijcard.2013.12.276"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","DOI":"10.1001\/jama.2013.282190"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: a systematic review and meta-analysis","DOI":"10.1007\/s40256-015-0134-3"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol","DOI":"10.1016\/S0735-1097(02)02134-4"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"A dobutamine paradox: eosinophilic myocarditis in the explanted heart of a 9-year-old girl undergoing cardiac transplantation","DOI":"10.1017\/S1047951105001411"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Dobutamine-induced eosinophilia","DOI":"10.1016\/j.amjcard.2003.12.069"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Barrett M, Fabre A, Tuohy G, et al. Eosinophilic myocarditis in patients on dobutamine therapy: an underappreciated and not uncommon phenomenon. Heart 2015;101(Suppl 5):A19-A.","DOI":"10.1136\/heartjnl-2015-308621.34"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Comparison of dopamine and norepinephrine in the treatment of shock","DOI":"10.1056\/NEJMoa0907118"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98:1329--34.","DOI":"10.1161\/01.CIR.98.13.1329"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"A prospective, randomized pilot study","DOI":"10.1097\/CCM.0b013e3181ffe0eb"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality","DOI":"10.1186\/s13054-016-1387-1"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients","DOI":"10.1007\/s00134-018-5222-9"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141-9;","DOI":"10.1016\/S0167-5273(01)00520-4"},{"key":"ref21","unstructured":"22. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986;73:Iii175-83."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","DOI":"10.1001\/jama.287.12.1541"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","DOI":"10.1016\/S0735-1097(02)02968-6"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","DOI":"10.1016\/j.jacc.2005.03.051"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"The PROMISE Study Research Group","DOI":"10.1056\/NEJM199111213252103"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Novel biologic mechanisms of levosimendan and its effect on the failing heart","DOI":"10.1517\/13543784.17.8.1143"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","DOI":"10.1016\/j.ijcard.2011.07.022"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","DOI":"10.1016\/S0140-6736(02)09455-2"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"A randomized, placebo-controlled, double-blind study (RUSSLAN)","DOI":"10.1053\/euhj.2001.3158"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","DOI":"10.1001\/jama.297.17.1883"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE","DOI":"10.1016\/j.ejheart.2005.12.003"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"A novel approach to improve cardiac performance: cardiac myosin activators","DOI":"10.1007\/s10741-009-9135-0"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil","DOI":"10.1038\/s41467-017-00176-5"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","DOI":"10.1126\/science.1200113"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study","DOI":"10.1016\/S0140-6736(11)61219-1"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","DOI":"10.1016\/S0140-6736(11)61126-4"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study","DOI":"10.1016\/j.jacc.2016.01.031"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Omecamtiv mecarbil: a promising new drug in systolic heart failure","DOI":"10.1093\/eurjhf\/hfr178"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Modulation of cardiac contractility by the phospholamban\/SERCA2a regulatome","DOI":"10.1161\/CIRCRESAHA.111.259754"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure","DOI":"10.1172\/JCI114429"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","DOI":"10.1016\/j.cardfail.2009.01.013"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","DOI":"10.1161\/CIRCULATIONAHA.111.022889"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","DOI":"10.1016\/S0140-6736(16)00082-9"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock","DOI":"10.1161\/01.CIR.67.3.620"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"dobutamine in acute decompensated heart failure patients on beta-blockers","DOI":"10.1093\/eurjhf\/hfq032"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Rafouli-Stergiou P, Parissis JT, Anastasiou-Nana M. Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option? Exp Opin Pharmacother2012;13:2637-47.","DOI":"10.1517\/14656566.2012.749859"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure","DOI":"10.1093\/eurheartj\/ehs332"},{"key":"ref49","unstructured":"50. Fowler MB, Alderman EL, Oesterle SN, et al. Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation 1984;70:I103-11."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery","DOI":"10.1053\/jcan.2001.23274"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery","DOI":"10.1213\/00000539-199804000-00001"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery","DOI":"10.1093\/bja\/aen367"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function","DOI":"10.1016\/j.athoracsur.2008.10.029"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","DOI":"10.1056\/NEJMoa1616218"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"The effects of levosimendan in cardiac surgery patients with poor left ventricular function","DOI":"10.1213\/01.ane.0000256863.92050.d3"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Sepsis and the heart","DOI":"10.1093\/bja\/aep339"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","DOI":"10.1097\/CCM.0000000000002255"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression","DOI":"10.1007\/s00134-005-2619-z"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials","DOI":"10.1016\/j.jcrc.2015.05.017"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articles\/Inotropes-in-Acute-Heart-Failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:46:19Z","timestamp":1783615579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindexcfr.2019.11.2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,4]]}},"URL":"https:\/\/doi.org\/10.15420\/cfr.2019.11.2","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,4]]}}}